Data Composite

Drug Recalls

Recent drug recall reports from the FDA (US) and Health Canada, newest first. Each entry links to the full record -- product description, reason for recall, and severity classification -- refreshed daily.

Bell Pharmaceuticals, Inc

US Class II Ongoing · initiated 2026-06-25

SubPotent Drug: low pH and significantly reduced assay (~0.6% vs expected ~6 7%).

Bell Pharmaceuticals, Inc

US Class II Ongoing · initiated 2026-06-25

SubPotent Drug: low pH and significantly reduced assay (~0.6% vs expected ~6 7%).

Bell Pharmaceuticals, Inc

US Class II Ongoing · initiated 2026-06-25

SubPotent Drug: low pH and significantly reduced assay (~0.6% vs expected ~6 7%).

Bell Pharmaceuticals, Inc

US Class II Ongoing · initiated 2026-06-25

SubPotent Drug: low pH and significantly reduced assay (~0.6% vs expected ~6 7%).

Bell Pharmaceuticals, Inc

US Class II Ongoing · initiated 2026-06-25

SubPotent Drug: low pH and significantly reduced assay (~0.6% vs expected ~6 7%).

Reliance Life Sciences Private Limited

US Class II Ongoing · initiated 2026-06-24

Lack of Sterility Assurance

Reliance Life Sciences Private Limited

US Class II Ongoing · initiated 2026-06-24

Lack of Sterility Assurance

Reliance Life Sciences Private Limited

US Class II Ongoing · initiated 2026-06-24

Lack of Sterility Assurance

Reliance Life Sciences Private Limited

US Class II Ongoing · initiated 2026-06-24

Lack of Sterility Assurance

QuVa Pharma, Inc.

US Class II Ongoing · initiated 2026-06-24

Failed Impurities/Degradation Specifications

JB Chemicals and Pharmaceuticals Ltd

US Class I Ongoing · initiated 2026-06-24

Cross Contamination with Other Products: Customer complaints for appearance of discolored tablets and red dots observed on Cetirizine Hydrochloride Tablets USP…

Padagis US LLC

US Class II Ongoing · initiated 2026-06-23

Subpotent Drug: Low out of specification assay results performed during long-term stability testing.

Direct Rx

US Class II Ongoing · initiated 2026-06-22

CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit

SUN PHARMACEUTICAL INDUSTRIES INC

US Class II Ongoing · initiated 2026-06-17

Labeling: Label Mix-up: 10mg Perampanel CIII tablet was found in a Perampanel CIII bottle labeled Perampanel 6 mg tablets.

Polyflex 25 g/vial powder for suspension

Canada Type II Ongoing · initiated 2026-06-17

Product quality. Verify if your product is affected.Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health co…

The Harvard Drug Group LLC

US Class II Ongoing · initiated 2026-06-16

Subpotent Drug

Lancora 5 mg tablet

Canada Type III Ongoing · initiated 2026-06-16

Product quality. Verify if your product is affected.Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health co…

Par Health USA, LLC

US Class II Ongoing · initiated 2026-06-12

Crystallization; identified as Buprenorphine free base

Boehringer Ingelheim Pharmaceuticals, Inc.

US Class II Ongoing · initiated 2026-06-12

CGMP Deviations: An incorrect detergent was used and the required swab sampling was not performed on a production hopper that had previously been used for a dif…

CareFusion 213, LLC

US Class II Ongoing · initiated 2026-06-11

Lack of assurance of sterility: Unsterilized ChloraPrep & PurPrep Applicators, intended for further processing and sterilization were instead distributed to cus…

CareFusion 213, LLC

US Class II Ongoing · initiated 2026-06-11

Lack of assurance of sterility: Unsterilized ChloraPrep & PurPrep Applicators, intended for further processing and sterilization were instead distributed to cus…

CareFusion 213, LLC

US Class II Ongoing · initiated 2026-06-11

Lack of assurance of sterility: Unsterilized ChloraPrep & PurPrep Applicators, intended for further processing and sterilization were instead distributed to cus…

CareFusion 213, LLC

US Class II Ongoing · initiated 2026-06-11

Lack of assurance of sterility: Unsterilized ChloraPrep & PurPrep Applicators, intended for further processing and sterilization were instead distributed to cus…

CareFusion 213, LLC

US Class II Ongoing · initiated 2026-06-11

Lack of assurance of sterility: Unsterilized ChloraPrep & PurPrep Applicators, intended for further processing and sterilization were instead distributed to cus…

CareFusion 213, LLC

US Class II Ongoing · initiated 2026-06-11

Lack of assurance of sterility: Unsterilized ChloraPrep & PurPrep Applicators, intended for further processing and sterilization were instead distributed to cus…